• Blog
  • Divalproex Sodium Market Report

    Divalproex Sodium Market Report

    Divalproex Sodium Market Report
    Report code - SR1151 Delivery - 2 Weeks
    Get Free Sample |
    Play Audio
    Listen
    Divalproex Sodium Market, Dynamics, Trends, Market Analysis
    See more...

    Impact of COVID-19 on Divalproex Sodium Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Divalproex Sodium Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Divalproex Sodium Market is estimated to grow from USD 2.1 billion in 2020 to USD 3.0 billion by 2026 at a healthy CAGR of 6.2% during the forecast period.

    Figure: Divalproex Sodium Market Size, 2020-2026 (USD Billion)

    Divalproex-Sodium-Market-Forecast

    Wish to get a free scope on this study? Click here.

    What is Divalproex sodium?

    Divalproex sodium is a Food and Drug Administrator (FDA) approved anti-epileptic drug which is used to treat migraine headaches, certain types of seizures, and manic episodes of bipolar disorders. It is widely known for its anti-convulsant properties for the treatment of epilepsy. It is also used in various combinational therapies.

    Key Players

    Key players operating in the divalproex sodium market are-

    • AbbVie (The U.S),
    • Mylan, Zydus Pharms USA,
    • Aurobindo Pharma (India),
    • Dr Reddys Labs (India),
    • LUPIN (India),
    • Orchid (India),
    • Sun Pharm (India), and
    • Teva (Israel).

    Market Dynamics

    Growing prevalence of bipolar disorders across the globe is augmenting the divalproex sodium market growth.

    • Also, the increasing patient pool across the globe affected the migraine and epilepsy headaches, thus propelling the product demand.
    • In addition, rising awareness towards diseases and several government initiatives to prevent head migraine is likely to boost the industry growth during the review period.

    Segment's Analysis

    Application Trends

    Based on application, the divalproex sodium market is classified into epilepsy, manic depressive illness, and others.

    • The epilepsy segment held a significant share in 2020 and is projected to grow at the highest CAGR during the assessment period.
    • This is mainly attributed to rising prevalence of epilepsy among kids and adults.
    • Also, as per WHO 2018 facts, around 50 million people were globally affected with epilepsy and around 80% of the people with epilepsy live in low- and middle-income countries which further bolsters the segment growth.

    Regional Trends

    By region, the North America market accounted for the largest share in 2020 and is expected to grow at a substantial CAGR in the following years.

    • This is mainly ascribed to rising government initiatives and increasing research & development for the introduction of new product are expected to aid in growth of the divalproex sodium market in the region.
    • In addition, strong healthcare infrastructure, increasing healthcare expenditure, and supportive reimbursement policies, further proliferates the regional market growth.

    COVID-19 Impact on Divalproex Sodium Market

    The COVID-19 outbreak has moderately affected the divalproex sodium industry. This is mainly attributed to shift of medical care towards coronavirus infected patients. However, rising cases of bipolar disorder due to stress during the pandemic, is expected to surge the product demand amid the pandemic.

    Critical Questions Answered in the Report

    • What are the key trends in the divalproex sodium market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the divalproex sodium market?
    • What are the key strategies adopted by the major vendors to lead in the divalproex sodium market?
    • What is the market share of the top vendors?

    Target Audience

    Here is the list of the group of customers that the Divalproex Sodium market hopes to have the greatest opportunity to convert-

    • Divalproex sodium vendors
    • Divalproex sodium retailers
    • Epilepsy organizations
    • Psychiatrists

    Wish to know more about the study? Click here

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].

    Frequently Asked Questions (FAQs)

    The divalproex sodium market size is expected to reach USD 3.0 billion in the foreseeable future.

    AbbVie (The U.S), Mylan, Zydus Pharms USA, Aurobindo Pharma (India), Dr Reddys Labs (India), LUPIN (India), Orchid (India), Sun Pharm (India) and Teva (Israel) are among the key players in the divalproex sodium market.

    The divalproex sodium market is expected to witness an impressive growth of 6.2% CAGR in the coming years.

    The epilepsy segment is expected to grow at the highest CAGR in the divalproex sodium market in the coming years.

    North America market accounted for the largest share in 2020 and is expected to grow at a substantial CAGR.

    Divalproex sodium vendors, Divalproex sodium retailers, Epilepsy organizations, Psychiatrists are the target audience in the divalproex sodium market.

    •